The industry analysts at Thomson Reuters put their heads together to tap the biggest new blockbusters in the making this year and surprised no one by capping the list with Gilead's Sovaldi.
No company likes to lose an integral part of its marketing team--and especially not to a competitor. Bristol-Myers Squibb is taking the news particularly personally, suing a former account manager and her new agency for misappropriation of trade secrets.
Bristol-Myers Squibb is re-upping with market-access outfit DKSH to dial up its commercialization efforts in Asia, extending a deal signed in 2010.
Three days after Bristol-Myers Squibb filed for FDA approval of the NS5A drug daclatasvir combined with asunaprevir, an NS3 protease inhibitor, the biotech company has turned over some of the Phase III cards it will be playing for an approval in markets around the world.
As Roche, Bristol-Myers Squibb and Merck race to the market with promising immunotherapies for advanced melanoma, analysts' sky-high sales estimates for the new drug class may soon have to reckon with revenue-slashing competition and pricing pressures.
What does $190 million in R&D spending get you? In the case of Alder Biopharmaceuticals, it got a blockbuster $1.35 billion development deal with Bristol-Myers Squibb and an in-house migraine drug headed into a Phase IIb study. It also takes the biotech to the threshold of an IPO it detailed today, which is designed to raise $115 million to fund operations through 2015.
When Bristol-Myers Squibb and Pfizer launched their new anticoagulant, Eliquis, early last year, Wall Street analysts predicted it would be a $3-billion-a-year blockbuster. After more than a year of struggling to reach that goal, the companies got some good news late Friday, when the FDA approved the drug to reduce the risk of blood clots in the legs and lungs following hip or knee replacement surgery.
Bristol-Myers Squibb, a leader in the race to develop new immuno-oncology therapies, is pairing up with Five Prime Therapeutics to come up with a second set of cancer therapies that target two undisclosed immune checkpoint pathways in a deal worth up to $350 million.
Ireland's liberal tax code continues to attract drugmakers, but some of the long-term players are cutting back on their extensive manufacturing there. Bristol-Myers Squibb, with plans to lay off about 160 workers at two facilities, can now be added to that list.
Bristol-Myers Squibb turned in improved financial results last year, in part by cutting costs after refining its focus, like its decision to drop its diabetes drug development partnership with AstraZeneca. The drugmaker is continuing that trend by tightening its manufacturing operations in Ireland and cutting about 160 jobs.